scholarly journals In vitro expansion of mesenchymal stem cells for clinical use

2016 ◽  
Vol 3 (02) ◽  
pp. 87 ◽  
Author(s):  
Phuc Van Pham ◽  
Ngoc Bich Vu
2017 ◽  
Vol 118 (10) ◽  
pp. 3072-3079 ◽  
Author(s):  
Annelise Pezzi ◽  
Bruna Amorin ◽  
Álvaro Laureano ◽  
Vanessa Valim ◽  
Alice Dahmer ◽  
...  

2019 ◽  
Vol 10 (10) ◽  
Author(s):  
Tongmeng Jiang ◽  
Guojie Xu ◽  
Qiuyan Wang ◽  
Lihui Yang ◽  
Li Zheng ◽  
...  

Following the publication of this article, the authors noticed that Fig. 5c in the original manuscript is incorrect due to an error in image handling during the creation of the figure. Specifically, the image for the group P3 BMSCs of time point 21d and the image in the group BMMNCs of time point 14d were incorrect. These linked to the group for BMMNCs of time point 21d, which was also, as a result, incorrect. An amendment to this paper has been published and can be accessed via a link at the top of the paper.


2011 ◽  
Vol 20 (5) ◽  
pp. 643-654 ◽  
Author(s):  
Antonella Poloni ◽  
Giulia Maurizi ◽  
Lucia Babini ◽  
Federica Serrani ◽  
Eleonora Berardinelli ◽  
...  

2008 ◽  
Vol 68 (11) ◽  
pp. 4229-4238 ◽  
Author(s):  
Reza Izadpanah ◽  
Deepak Kaushal ◽  
Christopher Kriedt ◽  
Fern Tsien ◽  
Bindiya Patel ◽  
...  

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 4865-4865
Author(s):  
Maximilian Christopeit ◽  
Marit Schendel ◽  
Lutz Peter Mueller ◽  
Gernot Keyszer ◽  
Gerhard Behre

Abstract Introduction. Mesenchymal stem cells (MSC) show immunosuppressive capacity in an allogeneic host. Severe progressive systemic sclerosis (SSc) is an autoimmune disease in which prognosis is worsened in individuals presenting with diffuse cutaneous, lung and renal involvement. Immunosuppression can improve the course of the disease. Methods. We transplanted a 41 year old female patient suffering from diffuse cutaneous systemic sclerosis with MSC from her father after in vitro expansion of the MSC. Results. The patient presented with a remarkable clinical response. Her ulcer surface decreased, the 17 Site Modified Rodnan Skin Score, vascular ultrasound, mouth aperture, the Visual Analogue Scale for pain (VAS), the Valentini Activity Score and the Hannover Functional Questionnaire showed encouraging improvements. The patient did not experience any adverse events during the first 300 days after transplantation. Conclusions. The transplantation of MSC from a haploidentical donor into a patient with systemic sclerosis is feasible, safe and effective. Furthermore is the transplantation of MSC from a haploidentical donor into an adult without severe pharmacological immunosuppression at the time of transplantation feasible and safe.


2015 ◽  
Vol 90 (1-3) ◽  
pp. 1-15 ◽  
Author(s):  
Courtney E. LeBlon ◽  
Meghan E. Casey ◽  
Caitlin R. Fodor ◽  
Tony Zhang ◽  
Xiaohui Zhang ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document